Biologics and Biosimilars

Biography

Biography: Mohan Dewan

Abstract

The talk will cover the patenting of inventions in the field of biologics in three important jurisdictions i.e. US, Europe and India and also the distinction between inventions in biologics and inventions relating to small molecule pharmaceutical compositions. Having said this several biologics patents are said to expire in the near future and after the next few years there is potential for Biosimilars to enter the market, particularly in the field of peptides, proteins, monoclonal antibodies and vaccines. Because biologic inventions deal with living cells, the conventional notions of biosimilarity cannot be applied to inventions of this type. The importance of the cell line and the process involving the use of these cell lines in new inventions relating to biologics needs to be fully understood. The next decade is likely to see patent works in the field of biologics. The patents acts throughout the world must keep pace with this development and specialist courts will be needed to understand the intricacies of this niche science.